An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review

Giulia Fornasier, Sara Francescon, Paolo Baldo

Research output: Contribution to journalReview article

Abstract

Colorectal cancer is the second most common cancer, representing 13% of all diagnosed cancers. Cetuximab is a recombinant chimeric monoclonal IgG1 antibody and epidermal growth factor receptor (EGFR) inhibitor. Cetuximab is approved for the first-line treatment in combination with chemotherapy or as a single agent in patients who have failed or are intolerant to chemotherapy in patients with EGFR-expressing, RAS wild-type metastatic colorectal cancer. Cetuximab efficacy emerged from studies that were conducted to approve the drug. Cetuximab is well tolerated; its toxicities are caused by its mechanism of action and the most common adverse reaction is skin toxicity. The main purpose of this manuscript is to present an update on the evidence-based summary of efficacy and safety and on the cost-effectiveness of cetuximab. Furthermore, it suggests a management of adverse drug reactions to improve the tolerability of the drug.

Original languageEnglish
Pages (from-to)1497-1509
Number of pages13
JournalAdvances in Therapy
Volume35
Issue number10
DOIs
Publication statusPublished - Oct 1 2018

Keywords

  • Adverse drug reactions
  • BRAF
  • Cetuximab
  • EGFR
  • Metastatic colorectal cancer

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review'. Together they form a unique fingerprint.

  • Cite this